Thomas Smith
Stock Analyst at Leerink Partners
(4.97)
# 85
Out of 4,396 analysts
678
Total ratings
54.1%
Success rate
47.5%
Average return
Main Sectors:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals | Initiated Coverage: Buy | $12 | $3.87 | +210.48% | 1 | Jun 2, 2026 | |
| IRON Disc Medicine | Reiterated: Buy | n/a | $68.34 | - | 27 | Jun 2, 2026 | |
| EQ Equillium | Upgraded: Buy | $6 | $2.70 | +122.22% | 34 | May 28, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | n/a | $6.85 | - | 17 | May 27, 2026 | |
| ALMS Alumis | Reiterated: Buy | $32 | $20.01 | +59.92% | 13 | May 15, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $106 | $76.44 | +38.67% | 1 | Apr 13, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $50 | $16.31 | +206.56% | 39 | Apr 6, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $52 → $50 | $31.61 | +58.18% | 37 | Apr 2, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | $10 | $11.14 | -10.19% | 7 | Mar 6, 2026 | |
| EVMN Evommune | Reiterated: Buy | $42 → $52 | $20.49 | +153.78% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $9.68 | +271.90% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.12 | - | 20 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $12 | $3.97 | +202.27% | 1 | Jan 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $32 | $7.85 | +307.64% | 18 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | kr 102.00 | $30.10 | +238.87% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $118 | $29.23 | +303.69% | 38 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.36 | - | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $4.30 | +62.79% | 34 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $104 → $115 | $102.72 | +11.95% | 17 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $73 → $14 | $17.80 | -21.35% | 32 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $780 | $884.00 | -11.76% | 35 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.60 | - | 40 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $476.89 | - | 39 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $6.52 | +298.77% | 15 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.55 | +125.35% | 34 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $10.07 | +247.57% | 52 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $11.89 | n/a | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $16.40 | n/a | 16 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $12.26 | n/a | 28 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $13.59 | n/a | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.57 | n/a | 25 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $1.19 | n/a | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $33 | $76.91 | n/a | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $10.17 | n/a | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $2 | $20.89 | n/a | 16 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 5,214p | $123.80 | n/a | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $21 | $7.06 | n/a | 1 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $6 | $1.88 | n/a | 1 | Sep 8, 2017 |
X4 Pharmaceuticals
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $3.87
Upside: +210.48%
Disc Medicine
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $68.34
Upside: -
Equillium
May 28, 2026
Upgraded: Buy
Price Target: $6
Current: $2.70
Upside: +122.22%
Cartesian Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.85
Upside: -
Alumis
May 15, 2026
Reiterated: Buy
Price Target: $32
Current: $20.01
Upside: +59.92%
Spyre Therapeutics
Apr 13, 2026
Reiterated: Buy
Price Target: $106
Current: $76.44
Upside: +38.67%
Viridian Therapeutics
Apr 6, 2026
Reiterated: Buy
Price Target: $50
Current: $16.31
Upside: +206.56%
Immunovant
Apr 2, 2026
Reiterated: Buy
Price Target: $52 → $50
Current: $31.61
Upside: +58.18%
Climb Bio
Mar 6, 2026
Reiterated: Buy
Price Target: $10
Current: $11.14
Upside: -10.19%
Evommune
Mar 6, 2026
Reiterated: Buy
Price Target: $42 → $52
Current: $20.49
Upside: +153.78%
Mar 3, 2026
Initiated Coverage: Buy
Price Target: $36
Current: $9.68
Upside: +271.90%
Jan 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.12
Upside: -
Jan 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $3.97
Upside: +202.27%
Dec 15, 2025
Reiterated: Buy
Price Target: $25 → $32
Current: $7.85
Upside: +307.64%
Nov 26, 2025
Initiated Coverage: Buy
Price Target: kr 102.00
Current: $30.10
Upside: +238.87%
Oct 23, 2025
Reiterated: Buy
Price Target: $118
Current: $29.23
Upside: +303.69%
Oct 21, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.36
Upside: -
Oct 15, 2025
Reiterated: Buy
Price Target: $7
Current: $4.30
Upside: +62.79%
Oct 8, 2025
Reiterated: Buy
Price Target: $104 → $115
Current: $102.72
Upside: +11.95%
Oct 1, 2025
Maintained: Buy
Price Target: $73 → $14
Current: $17.80
Upside: -21.35%
Sep 17, 2025
Reiterated: Buy
Price Target: $780
Current: $884.00
Upside: -11.76%
Aug 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $29.60
Upside: -
Aug 19, 2025
Maintained: Buy
Price Target: n/a
Current: $476.89
Upside: -
Aug 18, 2025
Reiterated: Buy
Price Target: $26
Current: $6.52
Upside: +298.77%
Aug 15, 2025
Reiterated: Buy
Price Target: $8
Current: $3.55
Upside: +125.35%
Aug 7, 2025
Reiterated: Buy
Price Target: $35
Current: $10.07
Upside: +247.57%
Apr 16, 2025
Maintained: Hold
Price Target: n/a
Current: $11.89
Upside: n/a
Aug 28, 2024
Reiterated: Buy
Price Target: $58
Current: $16.40
Upside: n/a
Aug 8, 2024
Maintained: Hold
Price Target: $5
Current: $12.26
Upside: n/a
Aug 8, 2024
Reiterated: Buy
Price Target: $6
Current: $13.59
Upside: n/a
Aug 7, 2024
Reiterated: Buy
Price Target: $7
Current: $3.57
Upside: n/a
Aug 7, 2024
Reiterated: Buy
Price Target: $46
Current: $1.19
Upside: n/a
Aug 7, 2024
Maintained: Hold
Price Target: $33
Current: $76.91
Upside: n/a
Mar 15, 2024
Maintained: Buy
Price Target: n/a
Current: $10.17
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: $13 → $2
Current: $20.89
Upside: n/a
Aug 8, 2022
Maintained: Buy
Price Target: 5,214p
Current: $123.80
Upside: n/a
Jan 17, 2019
Initiated Coverage: Hold
Price Target: $21
Current: $7.06
Upside: n/a
Sep 8, 2017
Initiated Coverage: Hold
Price Target: $6
Current: $1.88
Upside: n/a